Erlotinib customization based on epidermal growth factor receptor (EGFR) mutations in stage IV non-small-cell lung cancer (NSCLC) patients (p)
Authors:
- R. PortaRPR. Porta
- C. QueraltCQC. Queralt
- F. CardenalFCF. Cardenal
- C. MayoCMC. Mayo
- M. ProvencioMPM. Provencio
- C. CampsCCC. Camps
- D. IslaDID. Isla
- J. González-LarribaJGJ. González-Larriba
- M. TarónMTM. Tarón
- R. RosellRRR. Rosell
- 20 May 2008
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 26 (15_suppl) , 8038